Procopio’s Life Sciences Intellectual Property Litigation Practice and three of its attorneys were recognized by Patexia for outstanding performance in Hatch-Waxman/ANDA Litigation in multiple categories. Procopio ranked in the Top 10 out of more than 220 firms. Partners Jeremy Edwards and Steven Maddox ranked in the Top 25 out of nearly 2,000 attorneys, and Senior Counsel Brett Garrison ranked in the Top 100. Jeremy, Steven and Brett are all based in Procopio’s Washington, D.C., office.

Each year Patexia evaluates and ranks law firms and attorneys in various IP fields based on their performance, activity and success across a five-year period. The 2024 ANDA Intelligence Report analyzed more than 1,400 ANDA (Abbreviated New Drug Application) cases involving nearly 150 judges and more than 1,700 patents involving more than 460 pharmaceutical companies. Patexia notes the Hatch-Waxman/ANDA litigation space is highly competitive, with many law firms struggling to stand out and pharmaceutical companies searching for the best counsel.

Our award-winning ANDA litigation attorneys legal successes include:

• Successfully fending off Padagis Israel Pharmaceuticals Ltd.’s ANDA challenge to key Evofem Biosciences patents, ensuring continued patent protection for its hormone-free prescription birth control gel Phexxi® until 2033;
• Earning a complete victory for Amneal Pharmaceuticals over Noven Pharmaceuticals in connection with Amneal’s ANDA for a generic version of the Minivelle® estrogen patch;
• Persuading a unanimous Federal Circuit panel to affirm the decision of the U.S. Patent Trial and Appeal Board that all claims of six patents by Jazz Pharmaceuticals were invalid as obvious, paving the way for Amneal’s bid to market a therapeutic equivalent of Xyrem® for the treatment of narcolepsy;
• Persuading the Federal Circuit to vacate a trial decision rendered against Actavis after being brought on for the appeal;
• Securing a complete victory for Allergan in first-to-file litigation over Beyaz® and Safyral® (Merck and Bayer), persuading a unanimous Federal Circuit panel to reverse and invalidate the patents under the on-sale bar; and
• Scoring a complete non-infringement victory for Watson before the U.S. District Court for the District of Delaware, obtaining a rare, expedited trial culminating in a rare announcement from the bench of the judge’s decision immediately after the close of evidence, before any post-trial briefing.

Whether it’s a dispute in federal, state or appellate court or before the U.S. Patent and Trademark Office, Procopio’s IP Litigation team brings clients a deep bench of attorneys with decades of experience representing a wide range of companies from startups to Fortune 500 companies. Our Life Sciences attorneys bring you decades of law firm and in-house counsel experience—from life-saving pharmaceuticals to breakthrough biotechnologies—offering a unique understanding of your legal challenges and opportunities in your rapidly evolving, multidisciplinary industry. Learn more about our IP Litigation and Life Sciences practices.